Opinion|Videos|August 29, 2024

Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

Experts discuss American College of Rheumatology guidelines on transitioning patients from TNF inhibitors to non-TNF targeted therapies like Janus kinase inhibitors, as well as factors influencing treatment switching decisions in clinical practice.

Episodes in this series

Video content above is prompted by the following:

  • For patients receiving tumor necrosis factor (TNF) inhibitors, please describe American College of Rheumatology guidance on switching to a non-TNF targeted therapy, such as Janus kinase inhibitors, vs cycling.
  • In your own practice, what factors would make you consider switching?

Related Content